Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;8(1):3.
doi: 10.21037/cco.2018.12.03. Epub 2019 Jan 9.

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin

Affiliations
Free article
Review

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin

Saritha Kartan et al. Chin Clin Oncol. 2019 Feb.
Free article

Abstract

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. While most pcCD30+ T cell LPDs have an excellent prognosis, systemic lymphomas typically have a poorer outcome. CD30 has now been shown to be a reliable therapeutic target in pcCD30+ T cell LPDs. This review will emphasize the structure and function of CD30, along with the clinical and pathological spectrum of pcCD30+ T cell LPDs. It will also highlight other CD30+ lymphoproliferations that must be differentiated by careful clinical and pathological correlation.

Keywords: Cutaneous CD30+ T cell lymphoproliferative diseases; lymphomatoid papulosis (LyP); primary cutaneous anaplastic large cell lymphoma (pcALCL); spectrum.

PubMed Disclaimer

MeSH terms

LinkOut - more resources